BHC in the 13F filings
Bausch Health Cos Inc · CUSIP 071734107
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 28 Apr 2025
- latest of these filings; the earliest 12 Feb 2025
- Managers listing it
- 6
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 5 listed it in both
- Shares listed
- 42,350,464
- combined, among listed positions
- Reported value
- $341m
- combined, at the quarter end
Among the 94 comparable managers: 3 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing BHC in Q4 2024
6 of 6 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Carl C. Icahn | 34,721,118 | $280m | 3.77% | Held | 0 | 14 Feb 2025 (the filing on sec.gov) |
| Arrowstreet Capital LP | 4,770,793 | $39m | under 0.1% | Added | +1,510,445 | 12 Feb 2025 (the filing on sec.gov) |
| Oaktree Capital Management LP | 1,270,000 | $10m | 0.18% | Held | 0 | 12 Feb 2025 (the filing on sec.gov) |
| GAMCO Investors Inc | 1,075,141 | $8.7m | 0.09% | Added | +12,874 | 13 Feb 2025 (the filing on sec.gov) |
| Bridgewater Associates LP | 501,912 | $4.0m | under 0.1% | Added | n.a. | 13 Feb 2025 (the filing on sec.gov) |
| Elliott Investment Management LP | 11,500 | $93k | under 0.1% | Held | 0 | 28 Apr 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Arrowstreet Capital LPexisting position · 4,770,793 shares now+1,510,445
- GAMCO Investors Incexisting position · 1,075,141 shares now+12,874
Reductions
No reduction among listed positions.
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
- Maverick Capital Ltdwas $2.2m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2018 | 2 | $29m | n.a. | n.a. |
| Q3 2018 | 12 | $1.0bn | n.a. | n.a. |
| Q4 2018 | 14 | $718m | n.a. | n.a. |
| Q1 2019 | 13 | $1.1bn | n.a. | n.a. |
| Q2 2019 | 14 | $1.2bn | n.a. | n.a. |
| Q3 2019 | 10 | $982m | n.a. | n.a. |
| Q4 2019 | 10 | $1.5bn | n.a. | n.a. |
| Q1 2020 | 11 | $806m | n.a. | n.a. |
| Q2 2020 | 9 | $840m | n.a. | n.a. |
| Q3 2020 | 10 | $664m | n.a. | n.a. |
| Q4 2020 | 11 | $1.0bn | n.a. | n.a. |
| Q1 2021 | 12 | $2.3bn | n.a. | n.a. |
| Q2 2021 | 14 | $2.2bn | n.a. | n.a. |
| Q3 2021 | 10 | $2.0bn | n.a. | n.a. |
| Q4 2021 | 9 | $1.8bn | n.a. | n.a. |
| Q1 2022 | 13 | $1.5bn | n.a. | n.a. |
| Q2 2022 | 8 | $539m | n.a. | n.a. |
| Q3 2022 | 10 | $350m | n.a. | n.a. |
| Q4 2022 | 9 | $325m | n.a. | n.a. |
| Q1 2023 | 5 | $387m | n.a. | n.a. |
| Q2 2023 | 6 | $409m | n.a. | n.a. |
| Q3 2023 | 9 | $429m | n.a. | n.a. |
| Q4 2023 | 6 | $403m | 1 | 3 |
| Q1 2024 | 9 | $594m | 3 | 3 |
| Q2 2024 | 8 | $380m | 3 | 4 |
| Q3 2024 | 6 | $331m | 1 | 4 |
| Q4 2024 | 6 | $341m | 3 | 1 |
| Q1 2025 | 5 | $277m | 2 | 2 |
| Q2 2025 | 5 | $285m | 0 | 2 |
| Q3 2025 | 4 | $47m | 1 | 2 |
| Q4 2025 | 6 | $68m | 25 | 4 |
| Q1 2026 | 5 | $61m | 8 | 19 |
| Q2 2026 | 4 | $55m | 12 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BHC and LLY →BHC and JNJ →BHC and VRTX →Choose a stock to compare with BHC →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BHC, latest filings →Back to the 13F Explorer →